Amgen Inc
$ 355.20
0.32%
12 Jun - close price
- Market Cap 191,704,383,000 USD
- Current Price $ 355.20
- High / Low $ 358.17 / 351.96
- Stock P/E 24.68
- Book Value 17.03
- EPS 14.39
- Next Earning Report 2026-08-04
- Dividend Per Share $9.66
- Dividend Yield 2.73 %
- Next Dividend Date -
- ROA 0.08 %
- ROE 1.01 %
- 52 Week High 388.36
- 52 Week Low 260.01
About
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
Analyst Target Price
$352.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-02-03 | 2025-11-04 | 2025-08-05 | 2025-05-01 | 2025-02-04 | 2024-10-30 | 2024-08-06 | 2024-05-02 | 2024-02-06 | 2023-10-31 | 2023-08-03 |
| Reported EPS | 5.15 | 5.29 | 5.64 | 2.65 | 4.9 | 5.31 | 5.58 | 4.97 | 3.96 | 4.71 | 4.96 | 5 |
| Estimated EPS | 4.77 | 4.73 | 5.01 | 3.12 | 4.26 | 5.08 | 5.11 | 5 | 3.89 | 4.59 | 4.68 | 4.49 |
| Surprise | 0.38 | 0.56 | 0.63 | -0.47 | 0.64 | 0.23 | 0.47 | -0.03 | 0.07 | 0.12 | 0.28 | 0.51 |
| Surprise Percentage | 7.9665% | 11.8393% | 12.5749% | -15.0641% | 15.0235% | 4.5276% | 9.1977% | -0.6% | 1.7995% | 2.6144% | 5.9829% | 11.3586% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 5.55 |
| Currency | USD |
Previous Dividend Records
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-06-05 | 2026-03-06 | 2025-12-12 | 2025-09-12 | 2025-06-06 | 2025-03-07 | 2024-12-09 | 2024-09-06 | 2024-06-07 | 2024-03-07 |
| Amount | $2.52 | $2.52 | $2.38 | $2.38 | $2.38 | $2.38 | $2.25 | $2.25 | $2.25 | $2.25 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AMGN
2026-06-14 10:11:05
The Healthcare of Ontario Pension Plan Trust Fund reduced its stake in Amgen Inc. by 14.7% in the fourth quarter, selling 64,867 shares and retaining 376,191 shares valued at approximately $123.1 million. This reduction comes amidst mixed signals for Amgen, including strong recent earnings that topped expectations and raised FY 2026 guidance, but also significant regulatory uncertainty surrounding its drug Tavneos. Analysts currently hold a consensus "Hold" rating on AMGN with a target price of $354.12.
2026-06-14 07:59:00
Atlas Capital Advisors Inc. has reportedly acquired a new position in Amgen Inc. (NASDAQ:AMGN) worth approximately $2.20 million, purchasing 6,725 shares in the fourth quarter. Several other hedge funds also adjusted their holdings in Amgen, with the stock currently retaining a "Hold" rating from analysts and a consensus target price of $354.12. The article also highlights recent positive news regarding Amgen's drug pipeline for eye disease and obesity, alongside negative sentiment concerning a proposed FDA withdrawal for its drug Tavneos.
2026-06-14 06:20:03
Amgen (AMGN) stock valuation shows a split perspective: analysts suggest it's slightly overvalued at $352 compared to its current price of $355.20, while a Discounted Cash Flow (DCF) model indicates a significant undervaluation at $664. The discrepancy highlights differing assumptions about future cash flows and growth, particularly regarding its strong late-stage pipeline which includes therapies for obesity/diabetes and cardiovascular diseases. Investors are encouraged to form their own view given the mixed signals on potential upside versus market concerns.
2026-06-14 06:07:09
Morgan Stanley has increased its price target for Amgen (AMGN) from $322 to $340, while maintaining an 'Equal Weight' rating, citing the strong launch of Amgen's drug Uplizna for generalized myasthenia gravis (gMG). The firm predicts the gMG market could double to over $10 billion in the next five years due to new therapies and increased biologic adoption. Amgen's Uplizna received FDA approval last year for Immunoglobulin G4-related disease and European Commission approval for gMG in February 2026.
2026-06-14 05:17:05
Wall Street Zen has upgraded Amgen (NASDAQ:AMGN) from "hold" to "buy," contributing to a mixed but generally positive analyst sentiment for the company. Despite the upgrade, Amgen's average rating remains "Hold" with a consensus target price of $354.12, according to MarketBeat data. The company recently surpassed Q1 expectations with strong EPS and revenue, and its pipeline shows promise in areas like eye disease and obesity, though regulatory risks like a proposed FDA withdrawal for Tavneos remain a concern.
2026-06-13 11:12:03
Van ECK Associates Corp significantly reduced its stake in Amgen Inc. by 39.8% in Q4, selling over 540,000 shares. Despite this, other institutional investors increased their positions, and hedge funds collectively own a large portion of the company's stock. The article also details Amgen's recent financial performance, analyst ratings, insider trading activity, and key news impacting the biotechnology firm.
